deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT03417895

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy (PASSION)

Anti-PD-1 Antibody SHR-1210 Combined With Anti-angiogenesis Inhibitor Apatinib in Treatment of Extensive-stage Disease Small Cell Lung Cancer After Failure of First Line Standard Therapy

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Small-cell Lung Cancer
Interventions Apatinib SHR-1210
Updated 8 times since 2018 Last updated: Feb 25, 2024 Started: Apr 20, 2018 Primary completion: Aug 4, 2021 Completion: Aug 4, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Small-cell Lung Cancer, this trial is completed. The trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and has accumulated 8 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshotNot Yet Recruiting~Jun 2018 – ~Apr 2020 · 22 months · monthly snapshotNot Yet Recruiting~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshotUnknown Status~Jan 2021 – ~Sep 2022 · 20 months · monthly snapshotUnknown Status~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshotActive Not Recruiting~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Mar 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown Status → Active Not Recruiting

  5. Jan 2021 — Sep 2022 [monthly]

    Unknown Status PHASE2

▶ Show 3 earlier versions

  1. Apr 2020 — Jan 2021 [monthly]

    Unknown Status PHASE2

    Status: Not Yet Recruiting → Unknown Status

  2. Jun 2018 — Apr 2020 [monthly]

    Not Yet Recruiting PHASE2

  3. Feb 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jiangsu HengRui Medicine Co., Ltd.
Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations